Randomised trial of four-drug vs less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis
1996

Comparing Two Chemotherapy Regimens for Small-Cell Lung Cancer

Sample size: 310 publication Evidence: moderate

Author Information

Author(s): NM Bleehen, DJ Girling, P Hopwood, G Lallemand, D Machin, RJ Stephens, AJ Bailey

Primary Institution: Medical Research Council Lung Cancer Working Party

Hypothesis

Is a less intensive two-drug chemotherapy regimen as effective as a four-drug regimen in palliating symptoms and improving quality of life for patients with small-cell lung cancer and poor prognosis?

Conclusion

The two-drug regimen of etoposide and vincristine is a useful palliative treatment for patients with small-cell lung cancer and poor prognosis, with similar survival rates but less toxicity compared to the four-drug regimen.

Supporting Evidence

  • The four-drug regimen caused more toxicity, including higher rates of mucositis and hematological toxicity.
  • Survival rates were similar between the two treatment groups, with median survival of 141 days for the four-drug group and 137 days for the two-drug group.
  • Patients receiving the two-drug regimen reported less psychological distress and better quality of life outcomes.

Takeaway

Doctors tested two types of medicine to help people with a serious lung disease feel better. One type was easier on the body and worked just as well.

Methodology

Patients were randomly assigned to receive either a four-drug or a two-drug chemotherapy regimen, with assessments of quality of life, tumor response, and survival.

Potential Biases

Potential bias in self-reported quality of life measures and the risk of early death in the more intensive treatment group.

Limitations

The trial did not include patients over 80 years old and relied on patient-reported outcomes, which may have compliance issues.

Participant Demographics

310 patients, 63% male, 37% female, aged 80 years or less, with extensive or limited small-cell lung cancer and poor performance status.

Statistical Information

P-Value

0.9

Confidence Interval

0.79-1.24

Statistical Significance

p=0.9

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication